if you want to remove an article from website contact us from top.

    mr. buck has several family members who died from different cancers. he wants to know if medicare covers cancer screening. what should you tell him?

    James

    Guys, does anyone know the answer?

    get mr. buck has several family members who died from different cancers. he wants to know if medicare covers cancer screening. what should you tell him? from EN Bilgi.

    [House Hearing, 109 Congress]

    [From the U.S. Government Printing Office]

    WOMEN AND CANCER: WHERE ARE WE IN PREVENTION, EARLY DETECTION AND

    TREATMENT OF GYNECOLOGIC CANCERS?

    =======================================================================

    HEARING before the

    SUBCOMMITTEE ON CRIMINAL JUSTICE,

    DRUG POLICY, AND HUMAN RESOURCES

    of the COMMITTEE ON GOVERNMENT REFORM

    HOUSE OF REPRESENTATIVES

    ONE HUNDRED NINTH CONGRESS

    FIRST SESSION __________ SEPTEMBER 7, 2005 __________ Serial No. 109-128 __________

    Printed for the use of the Committee on Government Reform

    Available via the World Wide Web: http://www.gpoaccess.gov/congress/

    index.html

    http://www.house.gov/reform

    ______

    U.S. GOVERNMENT PRINTING OFFICE

    26-657 WASHINGTON : 2006

    _____________________________________________________________________________

    For Sale by the Superintendent of Documents, U.S. Government Printing Office

    Internet: bookstore.gpo.gov Phone: toll free (866) 512-1800; (202) 512�091800

    Fax: (202) 512�092250 Mail: Stop SSOP, Washington, DC 20402�090001

    COMMITTEE ON GOVERNMENT REFORM

    TOM DAVIS, Virginia, Chairman

    CHRISTOPHER SHAYS, Connecticut HENRY A. WAXMAN, California

    DAN BURTON, Indiana TOM LANTOS, California

    ILEANA ROS-LEHTINEN, Florida MAJOR R. OWENS, New York

    JOHN M. McHUGH, New York EDOLPHUS TOWNS, New York

    JOHN L. MICA, Florida PAUL E. KANJORSKI, Pennsylvania

    GIL GUTKNECHT, Minnesota CAROLYN B. MALONEY, New York

    MARK E. SOUDER, Indiana ELIJAH E. CUMMINGS, Maryland

    STEVEN C. LaTOURETTE, Ohio DENNIS J. KUCINICH, Ohio

    TODD RUSSELL PLATTS, Pennsylvania DANNY K. DAVIS, Illinois

    CHRIS CANNON, Utah WM. LACY CLAY, Missouri

    JOHN J. DUNCAN, Jr., Tennessee DIANE E. WATSON, California

    CANDICE S. MILLER, Michigan STEPHEN F. LYNCH, Massachusetts

    MICHAEL R. TURNER, Ohio CHRIS VAN HOLLEN, Maryland

    DARRELL E. ISSA, California LINDA T. SANCHEZ, California

    GINNY BROWN-WAITE, Florida C.A. DUTCH RUPPERSBERGER, Maryland

    JON C. PORTER, Nevada BRIAN HIGGINS, New York

    KENNY MARCHANT, Texas ELEANOR HOLMES NORTON, District of

    LYNN A. WESTMORELAND, Georgia Columbia

    PATRICK T. McHENRY, North Carolina ------

    CHARLES W. DENT, Pennsylvania BERNARD SANDERS, Vermont

    VIRGINIA FOXX, North Carolina (Independent)

    ------ ------

    Melissa Wojciak, Staff Director

    David Marin, Deputy Staff Director/Communications Director

    Rob Borden, Parliamentarian/Senior Counsel

    Teresa Austin, Chief Clerk

    Phil Barnett, Minority Chief of Staff/Chief Counsel

    Subcommittee on Criminal Justice, Drug Policy, and Human Resources

    MARK E. SOUDER, Indiana, Chairman

    PATRICK T. McHenry, North Carolina ELIJAH E. CUMMINGS, Maryland

    DAN BURTON, Indiana BERNARD SANDERS, Vermont

    JOHN L. MICA, Florida DANNY K. DAVIS, Illinois

    GIL GUTKNECHT, Minnesota DIANE E. WATSON, California

    STEVEN C. LaTOURETTE, Ohio LINDA T. SANCHEZ, California

    CHRIS CANNON, Utah C.A. DUTCH RUPPERSBERGER, Maryland

    CANDICE S. MILLER, Michigan MAJOR R. OWENS, New York

    GINNY BROWN-WAITE, Florida ELEANOR HOLMES NORTON, District of

    VIRGINIA FOXX, North Carolina Columbia

    Ex Officio

    TOM DAVIS, Virginia HENRY A. WAXMAN, California

    J. Marc Wheat, Staff Director and Chief Counsel

    Michelle Powers, Counsel

    Malia Holst, Clerk

    Richard Butcher, Minority Professional Staff Member

    C O N T E N T S ---------- Page

    Hearing held on September 7, 2005................................ 1

    Statement of:

    Karlan, Dr. Beth, president, Society of Gynecologic

    Oncologists; Dr. Mark Jay Rosenfeld, scientist/researcher;

    Sheryl Silver, sister of Johanna Silver; and Kolleen

    Stacey, ovarian cancer survivor............................ 71

    Karlan, Dr. Beth......................................... 71

    Rosenfeld, Dr. Mark Jay.................................. 78

    Silver, Sheryl........................................... 86

    Stacey, Kolleen.......................................... 94

    Trimble, Dr. Edward L., M.D., M.P.H., head of the surgery

    section, Division of Cancer Treatment and Diagnosis,

    National Cancer Institute; Dr. Ed Thompson, M.D., M.P.H.,

    Chief of Public Health Practice, Centers for Disease

    Control and Prevention; and Dr. Richard Pazdur, M.D.,

    Director, Division of Oncology Drug Products, Center for

    Drug Evaluation and Research, U.S. Food and Drug

    Administration............................................. 15

    Pazdur, Dr. Richard...................................... 33

    Thompson, Dr. Ed......................................... 24

    Trimble, Dr. Edward L.................................... 15

    Letters, statements, etc., submitted for the record by:

    Karlan, Dr. Beth, president, Society of Gynecologic

    Source : www.govinfo.gov

    AHIP Module 1 Quiz 4 Flashcards

    Study with Quizlet and memorize flashcards terms like Mr. Patel is in good health and is preparing a budget in anticipation of his retirement when he turns 66. He wants to understand the health care costs he might be exposed to under Medicare if he were to require hospitalization as a result of an illness. In general terms, what could you tell him about his costs for inpatient hospital services under Original Medicare?, Mrs. Shields is covered by Original Medicare. She sustained a hip fracture and is being successfully treated for that condition. However, she and her physicians feel that after her lengthy hospital stay she will need a month or two of nursing and rehabilitative care. What should you tell them about Original Medicare's coverage of care in a skilled nursing facility?, Mr. Rainey is experiencing paranoid delusions and his physician feels that he should be hospitalized. What should you tell Mr. Rainey (or his representative) about the length of an inpatient psychiatric hospital stay that Medicare will cover? and more.

    AHIP Module 1 Quiz 4

    5.0 9 Reviews

    Mr. Patel is in good health and is preparing a budget in anticipation of his retirement when he turns 66. He wants to understand the health care costs he might be exposed to under Medicare if he were to require hospitalization as a result of an illness. In general terms, what could you tell him about his costs for inpatient hospital services under Original Medicare?

    Click card to see definition 👆

    b. Under Original Medicare, there is a single deductible amount due for the first 60 days of any inpatient hospital stay, after which it converts into a per-day amount through day 90. After day 90, he would pay a daily amount up to 60 days over his lifetime, after which he would be responsible for all costs

    Click again to see term 👆

    Mrs. Shields is covered by Original Medicare. She sustained a hip fracture and is being successfully treated for that condition. However, she and her physicians feel that after her lengthy hospital stay she will need a month or two of nursing and rehabilitative care. What should you tell them about Original Medicare's coverage of care in a skilled nursing facility?

    Click card to see definition 👆

    c. Medicare will cover Mrs. Schmidt's skilled nursing services provided during the first 20 days of her stay, after which she would have a coinsurance until she has been in the facility for 100 days

    Click again to see term 👆

    1/7 Created by Stephanie_Burket

    Terms in this set (7)

    Mr. Patel is in good health and is preparing a budget in anticipation of his retirement when he turns 66. He wants to understand the health care costs he might be exposed to under Medicare if he were to require hospitalization as a result of an illness. In general terms, what could you tell him about his costs for inpatient hospital services under Original Medicare?

    b. Under Original Medicare, there is a single deductible amount due for the first 60 days of any inpatient hospital stay, after which it converts into a per-day amount through day 90. After day 90, he would pay a daily amount up to 60 days over his lifetime, after which he would be responsible for all costs

    Mrs. Shields is covered by Original Medicare. She sustained a hip fracture and is being successfully treated for that condition. However, she and her physicians feel that after her lengthy hospital stay she will need a month or two of nursing and rehabilitative care. What should you tell them about Original Medicare's coverage of care in a skilled nursing facility?

    c. Medicare will cover Mrs. Schmidt's skilled nursing services provided during the first 20 days of her stay, after which she would have a coinsurance until she has been in the facility for 100 days

    Mr. Rainey is experiencing paranoid delusions and his physician feels that he should be hospitalized. What should you tell Mr. Rainey (or his representative) about the length of an inpatient psychiatric hospital stay that Medicare will cover?

    b. Medicare will cover a total of 190 days of inpatient psychiatric care during Mr. Rainey's entire lifetime.

    Mrs. Quinn has just turned 65 and received a letter informing her that she has been automatically enrolled in Medicare Part B. She wants to understand what this means. What should you tell Mrs. Quinn?

    c. Part B primarily covers physician services. She will be paying a monthly premium and, with the exception of many preventive and screening tests, generally will have 20% co-payments for these services, in addition to an annual deductible.

    Mr. Buck has several family members who died from different cancers. He wants to know if Medicare covers cancer screening. What should you tell him?

    d. Medicare covers periodic performance of a range of screening tests that are meant to provide early detection of disease. Mr. Buck will need to check specific tests before obtaining them to see if they will be covered.

    Mrs. Turner is comparing her employer's retiree insurance to Original Medicare and would like to know which of the following services Original Medicare will cover if the appropriate criteria are met? What could you tell her?

    a. Original Medicare covers ambulance services.

    Mrs. Wolf wears glasses and dentures and has enjoyed considerable pain relief from arthritis through acupuncture. She is concerned about whether or not Medicare will cover these items and services. What should you tell her?

    a. Medicare does not cover acupuncture, or, in general, glasses or dentures.

    Sets with similar terms

    AHIP TRAINING Module 1

    28 terms Belinda_Williams6

    AHIP Module 1 Training

    31 terms jacob_page5 Medicare scenarios 53 terms mamagillry

    Medicare A and B What is Covered

    13 terms Kim_Goetz

    Sets found in the same folder

    AHIP module 1 28 terms david_johnson4841 AHIP Module 5 53 terms jacob_page5 2022 AHIP 168 terms yuting_wu75 Medicare exam 109 terms Belinda_Williams6

    Other sets by this creator

    AHIP Module 1 Quiz 6

    5 terms Stephanie_Burket

    AHIP Module 1 Quiz 5

    3 terms Stephanie_Burket

    AHIP Module 1 Quiz 3

    2 terms Stephanie_Burket

    AHIP Module 1 Quiz 2

    Source : quizlet.com

    Prostate Cancer

    Worldwide, prostate cancer is the most commonly diagnosed male malignancy and the fourth leading cause of cancer death in men.[1][2] This amounted to 1,414,249 newly diagnosed cases and 375,000 deaths worldwide yearly from this disease in 2020.[1][2][3][4][5]

    An official website of the United States government

    Log in Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation Bookshelf

    Browse Titles Advanced

    Help

    StatPearls [Internet].

    Show details

    Prostate Cancer

    Stephen W. Leslie; Taylor L. Soon-Sutton; Hussain Sajjad; Larry E. Siref.

    Author Information

    Last Update: May 12, 2022.

    Go to:

    Continuing Education Activity

    Worldwide, prostate cancer is the most commonly diagnosed malignancy and the sixth leading cause of cancer death in men. Diagnosis is primarily based on prostate-specific antigen (PSA) testing, MRI scans, and prostate tissue biopsies, although PSA testing for screening remains controversial. New diagnostic technologies including risk stratification bioassay tests, germline testing, and various PET scans are now available. When the cancer is limited to the prostate, it is considered localized and potentially curable. If the disease has spread outside the prostate, bisphosphonates, rank ligand inhibitors, hormonal treatment, chemotherapy, radiopharmaceuticals, immunotherapy, focused radiation, and other targeted therapies can be used. This activity is a current, comprehensive review of the evaluation and management of patients with prostate cancer and highlights the role of the interprofessional team in improving care for affected patients.

    Objectives:

    Describe the etiology of prostate cancer.

    Review the pathophysiologic basis of prostate cancer.

    Outline how to properly manage a patient affected by prostate cancer.

    Summarize how an optimally functioning interprofessional team would coordinate care to enhance outcomes for patients with prostate cancer.

    Access free multiple choice questions on this topic.

    Go to:

    Introduction

    Worldwide, prostate cancer is the most commonly diagnosed male malignancy and the fourth leading cause of cancer death in men.[1][2] This amounted to 1,414,249 newly diagnosed cases and 375,000 deaths worldwide yearly from this disease in 2020.[1][2][3][4][5]

    Fortunately, most prostate cancers tend to grow slowly and are low-grade with relatively low risk and limited aggressiveness.[6]

    There are no initial or early symptoms in most cases, but late symptoms may include fatigue due to anemia, bone pain, paralysis from spinal metastases, and renal failure from bilateral ureteral obstruction.

    Diagnosis is primarily based on prostate-specific antigen (PSA) testing and transrectal ultrasound-guided (TRUS) prostate tissue biopsies, although PSA testing for screening remains controversial.[7][8]

    Newer diagnostic modalities include free and total PSA levels, PCA3 urine testing, Prostate Health Index scoring (PHI), the"4K" test, exosome testing, genomic analysis, MRI imaging, PIRADS scoring, and MRI-TRUS fusion guided biopsies.[9]

    When the cancer is limited to the prostate, it is considered localized and potentially curable.[10]

    If the disease has spread to the bones or elsewhere outside the prostate, pain medications, bisphosphonates, rank ligand inhibitors, hormonal treatment, chemotherapy, radiopharmaceuticals, immunotherapy, focused radiation, and other targeted therapies can be used. Outcomes depend on age, associated health problems, tumor histology, and the extent of cancer.[11]

    Go to:

    Etiology

    The known major risk factors are age, ethnicity, obesity, and family history.[12]

    The overall incidence increases as people get older, but fortunately, cancer aggressiveness decreases with age.[13]

    Prostate cancer risk factors include male gender, older age, positive family history, increased height, obesity, hypertension, lack of exercise, persistently elevated testosterone levels, Agent Orange exposure, and ethnicity.[14][15][16]

    5 Alpha-Reductase Inhibitors

    These inhibitors, such as finasteride and dutasteride, may decrease low-grade cancer incidence, but they do not appear to affect high-grade risk and thus, do not significantly improve survival. These medications will reduce PSA levels by about 50%, which must be accounted for when comparing sequential prostate-specific antigen (PSA) readings.[17][18][19][20] Taking 5-alpha reductase inhibitors does not appear to affect prostate cancer risk.[21] The Health Professionals Follow-up Study examined the use of 5 alpha-reductase and prostate cancer in 38,000 men followed for over 20 years. Men taking the medication received more PSA tests, prostate examinations, and biopsies, but no association was found regarding the development of lethal disease, overall survival, or cancer-specific survival. Rates of overall and localized disease were reduced in men taking 5-alpha-reductase medications.[20][22]

    Genetics

    The cause of prostate cancer is unclear, but genetics is certainly involved. Genetic background, ethnicity, and family history are all known to contribute to prostate cancer risk.[23] In general, patients with genetic or hereditary prostate cancer tend to develop their malignancies at an earlier age, have more rapid progression, are more likely to be locally advanced, and have a higher risk of recurrence after surgery.[24] Hereditary prostate cancer has the highest heritability of any major cancer in men.[25] A family history of hereditary breast and ovarian cancer or Lynch syndrome increases the risk of prostate cancer, indicating a genetic connection.[26][27]

    Source : www.ncbi.nlm.nih.gov

    Do you want to see answer or more ?
    James 3 day ago
    4

    Guys, does anyone know the answer?

    Click For Answer